Marta Dueñas

This study identifies baseline intratumoral TCRβ and TCRγ repertoire features as predictors of response to immune checkpoint inhibitors in advanced RCC.

This study develops genetically engineered mouse models of advanced bladder cancer to investigate cell-of-origin and driver mutations, revealing subtype-specific characteristics and therapeutic responses.

This study identifies CD44v6 as a driver of bladder cancer aggressiveness and chemoresistance, linking its expression to poor patient outcomes and therapeutic resistance.

This study detects cancer gene mutations in saliva and plasma of Fanconi anemia patients to predict oral cancer and precursor lesions, finding that mutations correlate with disease development.